Evidence map›Paper›PMID 36677942›Full record

ReviewMolecules (Basel, Switzerland)2023

Ca

Razan Orfali, Nora Albanyan

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. KFrontiers in pharmacology · 2026
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Computational Ligand-Binding Site Prediction.Advances in experimental medicine and biology · 2026
    Review
  8. Review
  9. Visualization of KACS pharmacology & translational science · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Therapeutic efficacy of the BKCa channel opener chlorzoxazone in a mouse model of Fragile X syndrome.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Article
  15. Article
  16. Potential Targeting Mechanisms for Bone-Directed Therapies.International journal of molecular sciences · 2024
    Review
  17. Article
  18. Review
  19. Exploring the Impact of BKInternational journal of molecular sciences · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Razan OrfaliBiomedical Research Administration, Research Centre, King Fahad Medical City, Riyadh 12231, Saudi Arabia.ORCID 0000-0002-0584-4013
Nora AlbanyanClinical Pharmacy Administration, King Fahad Medical City, Riyadh 12231, Saudi Arabia.
King Fahd Medical City · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Ca

Indexed as

Intermediate-Conductance Calcium-Activated Potassium ChannelsPotassium ChannelsCalciumCell MembraneMembrane PotentialsPotassiumSmall-Conductance Calcium-Activated Potassium ChannelsCalciumIntermediate-Conductance Calcium-Activated Potassium ChannelsPotassiumPotassium ChannelsSmall-Conductance Calcium-Activated Potassium ChannelsCa2+-activated potassium channelsCa2+ sensitivitychannelopathiesKCa 1.1KCa2.x and KCa3.1 channels

Identifiers

PMID36677942
PMCPMC9861210
OpenAlexW4316467823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.